| ［1］ |
Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP［J］. J Dermatol, 2018,45（11）:1235⁃1270. doi: 10.1111/1346⁃8138.14523.
|
| ［2］ |
Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis ⁃ a model disease for specific targeted immunotherapy, systematic review［J］. Exp Dermatol, 2018,27（10）:1067⁃1077. doi: 10.1111/exd.13699.
|
| ［3］ |
Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52⁃week analysis from phase III open⁃label multicenter Japanese study［J］. J Dermatol, 2016,43（9）:1011⁃1017. doi: 10.1111/1346⁃ 8138.13306.
|
| ［4］ |
Cordoro KM, Ucmak D, Hitraya⁃Low M, et al. Response to interleukin （IL）⁃17 inhibition in an adolescent with severe manifestations of IL⁃36 receptor antagonist deficiency （DITRA） ［J］. JAMA Dermatol, 2017,153（1）:106⁃108. doi: 10.1001/jamadermatol.2016.3490.
|
| ［5］ |
Molho⁃Pessach V, Alyan R, Gordon D, et al. Secukinumab for the treatment of deficiency of interleukin 36 receptor antagonist in an adolescent［J］. JAMA Dermatol, 2017,153（5）:473⁃475. doi: 10.1001/jamadermatol.2016.5705.
|
| ［6］ |
Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: a case report and review of published work［J］. J Dermatol, 2018,45（11）:1353⁃1356. doi: 10.1111/1346⁃8138.14636.
|
| ［7］ |
Köstner K, Prelog M, Almanzar G, et al. Successful use of secukinumab in a 4⁃year⁃old patient with deficiency of interleukin⁃36 antagonist［J］. Rheumatology （Oxford）, 2018,57（5）:936⁃938. doi: 10.1093/rheumatology/kex510.
|
| ［8］ |
Nishida M, Takeichi T, Kono M, et al. Successful secukinumab treatment of recalcitrant juvenile generalized pustular psoriasis［J］. J Dermatol, 2020,47（3）:e77⁃e78. doi: 10.1111/1346⁃8138. 15228.
|
| ［9］ |
Wilsmann⁃Theis D, Schnell LM, Ralser⁃Isselstein V, et al. Successful treatment with interleukin⁃17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations［J］. J Dermatol, 2018,45（7）:850⁃854. doi: 10.1111/1346⁃8138.14318.
|
